Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27908161 | 0.86 | KDM1A (0.46) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15212170 | 0.81 | KDM1A (0.45) | KDM1AMAOBMAOAKCNH2SLC6A4 | |
| SCHEMBL3045300 | 0.77 | KDM1A (0.41) | KDM1AMAOBMAOA | |
| SCHEMBL15554113 | 0.76 | SLC9A1 (0.42) | KDM1ASLC6A3SLC6A2 | |
| SCHEMBL27991097 | 0.75 | KDM1A (0.54) | KDM1AMAOBMAOA | |
| SCHEMBL27908354 | 0.72 | KDM1A (0.41) | KDM1AMAOBMAOA | |
| SCHEMBL15540596 | 0.72 | HTR2A (0.40) | KCNH2 | |
| SCHEMBL27898196 | 0.71 | KDM1A (0.40) | KDM1AMAOBMAOA | |
| SCHEMBL27898192 | 0.70 | KDM1A (0.40) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15552976 | 0.70 | CFD (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| EP-1848695-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006087169-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | KDM1A 3326/4885MAOB 1930/4885MAOA 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.